COLUMBIA Care has launched its Ceed medicinal product range in the United Kingdom.
The UK launch of the patent-pending proprietary capsule UK follows its successful commercialisation in the United States.
In a press release the Canadian Securities Exchange-listed business says the capsules incorporate a portfolio of primary and secondary cannabinoids, available in a number of formulations with various THC and CBD doses.
Nicholas Vita, CEO, New York-headquartered Columbia Care, said it had ‘worked diligently to bring a product to market that fulfils a significant unmet patient and physician need in the UK’.
As the UK’s medical cannabis market continues to grow, this formulation has been introduced in response to physician and patient demand for more precise dosing options as well as more familiar form factors in cannabinoid-based medicinal product (CBMP), says the company.
Prior to the launch of Columbia Care’s solid-fill cannabis powder capsules, UK patients’ and physicians’ formulation options for CBMPs had been limited to cannabis flower and sublingual tinctures made with cannabis extracts, the release adds.
“Our solid-fill capsule provides numerous advantages for the patient. We believe this has the potential to truly drive normalisation around cannabis use for physicians and patients alike,” said Rosemary Mazanet, MD/PhD, Chief Scientific Officer, Columbia Care.
Columbia Care’s partners in the UK are IPS Pharma, and Grow Pharma, its market access partner.
